Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Predicting progression of MGUS/SMM

Niccolò Bolli • 15 Sep 2019
IMW 2019
Multiple Myeloma

Niccolò Bolli, MD, PhD, from the University of Milan, Milan, Italy, talks about predicting the risk of progression from precursor conditions and how they vary from active myeloma. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Niccolò Bolli

The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
2:52
Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
Niccolò Bolli • 25 Sep 2022
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
2:45
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli • 25 Aug 2022
Session highlights: clonal hematopoiesis in multiple myeloma
2:43
Session highlights: clonal hematopoiesis in multiple myeloma
Niccolò Bolli • 25 Aug 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Niccolò Bolli • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Niccolò Bolli • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Niccolò Bolli • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Niccolò Bolli • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals